GC Biopharma Corp.

KOSE:A006280 Stock Report

Market Cap: ₩1.5t

GC Biopharma Valuation

Is A006280 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A006280 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A006280 (₩130100) is trading above our estimate of fair value (₩106399.27)

Significantly Below Fair Value: A006280 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A006280?

Key metric: As A006280 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A006280. This is calculated by dividing A006280's market cap by their current revenue.
What is A006280's PS Ratio?
PS Ratio0.9x
Sales₩1.62t
Market Cap₩1.48t

Price to Sales Ratio vs Peers

How does A006280's PS Ratio compare to its peers?

The above table shows the PS ratio for A006280 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average29.5x
A298380 ABL Bio
45.4x25.5%₩1.5t
A007390 NatureCellLtd
59.1xn/a₩1.7t
A302440 SK bioscienceLtd
9.8x8.2%₩3.6t
A086900 Medy-Tox
3.6x12.5%₩883.1b
A006280 GC Biopharma
0.9x8.8%₩1.5t

Price-To-Sales vs Peers: A006280 is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (29.5x).

Price to Sales Ratio vs Industry

How does A006280's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.8x34.4%
A006280 GC Biopharma
 0.9x8.8%US$1.07b
A096530 Seegene
2.7x14.5%US$734.93m
A086900 Medy-Tox
3.6x12.5%US$634.10m
A006280 0.9xIndustry Avg. 8.8xNo. of Companies27PS01632486480+
27 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.8x66.0%
A006280 GC Biopharma
 0.9x104.4%US$1.07b
No more companies

Price-To-Sales vs Industry: A006280 is good value based on its Price-To-Sales Ratio (0.9x) compared to the KR Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is A006280's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A006280 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio2.4x

Price-To-Sales vs Fair Ratio: A006280 is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A006280 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩130,100.00
₩200,000.00
+53.7%
2.9%₩210,000.00₩190,000.00n/a6
Nov ’25₩152,200.00
₩195,000.00
+28.1%
6.5%₩210,000.00₩170,000.00n/a6
Oct ’25₩151,500.00
₩176,666.67
+16.6%
10.2%₩200,000.00₩150,000.00n/a6
Sep ’25₩170,900.00
₩167,428.57
-2.0%
9.4%₩200,000.00₩150,000.00n/a7
Aug ’25₩144,400.00
₩158,666.67
+9.9%
5.7%₩170,000.00₩150,000.00n/a6
Jul ’25₩115,800.00
₩146,333.33
+26.4%
3.1%₩150,000.00₩140,000.00n/a6
Jun ’25₩114,700.00
₩146,333.33
+27.6%
3.1%₩150,000.00₩140,000.00n/a6
May ’25₩114,300.00
₩144,666.67
+26.6%
3.3%₩150,000.00₩140,000.00n/a6
Apr ’25₩123,300.00
₩145,000.00
+17.6%
3.4%₩150,000.00₩140,000.00n/a6
Mar ’25₩117,900.00
₩146,428.57
+24.2%
4.0%₩155,000.00₩140,000.00n/a7
Feb ’25₩109,900.00
₩146,428.57
+33.2%
4.0%₩155,000.00₩140,000.00n/a7
Jan ’25₩125,500.00
₩146,428.57
+16.7%
6.5%₩160,000.00₩130,000.00n/a7
Dec ’24₩114,900.00
₩147,857.14
+28.7%
7.2%₩160,000.00₩130,000.00n/a7
Nov ’24₩97,800.00
₩149,285.71
+52.6%
6.8%₩160,000.00₩130,000.00₩152,200.007
Oct ’24₩108,700.00
₩156,428.57
+43.9%
2.8%₩160,000.00₩150,000.00₩151,500.007
Sep ’24₩113,000.00
₩156,428.57
+38.4%
2.8%₩160,000.00₩150,000.00₩170,900.007
Aug ’24₩114,500.00
₩156,428.57
+36.6%
2.8%₩160,000.00₩150,000.00₩144,400.007
Jul ’24₩114,800.00
₩159,857.14
+39.2%
6.9%₩180,000.00₩140,000.00₩115,800.007
Jun ’24₩128,500.00
₩158,625.00
+23.4%
6.8%₩180,000.00₩140,000.00₩114,700.008
May ’24₩123,600.00
₩159,888.89
+29.4%
6.7%₩180,000.00₩140,000.00₩114,300.009
Apr ’24₩122,100.00
₩164,250.00
+34.5%
6.7%₩180,000.00₩150,000.00₩123,300.008
Mar ’24₩119,800.00
₩171,750.00
+43.4%
10.1%₩210,000.00₩150,000.00₩117,900.008
Feb ’24₩131,700.00
₩176,750.00
+34.2%
8.2%₩210,000.00₩160,000.00₩109,900.008
Jan ’24₩129,500.00
₩176,750.00
+36.5%
8.2%₩210,000.00₩160,000.00₩125,500.008
Dec ’23₩129,000.00
₩184,555.56
+43.1%
14.1%₩247,000.00₩160,000.00₩114,900.009
Nov ’23₩127,500.00
₩204,555.56
+60.4%
15.6%₩247,000.00₩164,000.00₩97,800.009

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

7D

0.9%

1Y

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

7D

-5.8%

1Y

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

7D

1.7%

1Y

-39.0%